Search

Your search keyword '"van 't Hof, Arnoud W.J."' showing total 239 results
Start Over Author "van 't Hof, Arnoud W.J."
Sorry, I don't understand your search. ×
239 results on '"van 't Hof, Arnoud W.J."'

5. Prehospital treatment with zalunfiban (RUC-4) in patients with ST‐ elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial

Author

Rikken, Sem A.O.F., Selvarajah, Abi, Hermanides, Renicus S., Coller, Barry S., Gibson, C. Michael, Granger, Christopher B., Lapostolle, Frédéric, Postma, Sonja, van de Wetering, Henri, van Vliet, Risco C.W., Montalescot, Gilles, ten Berg, Jurriën M., and van ’t Hof, Arnoud W.J.

Published
2023
Full Text
View/download PDF

11. 2023 European Society of Cardiology guidelines for the management of acute coronary syndromes: Statement of endorsement by the NVVC

Author

Arts Assistenten Cardiologie, Team Medisch, Zwart, Bastiaan, Claessen, Bimmer E.P.M., Damman, Peter, Woudstra, Pier, Vink, Maarten A., Balder, J. Willem, Dickinson, Michael G., Badings, Erik A., Appelman, Yolande, van ’t Hof, Arnoud W.J., ten Berg, Jurriën M., Arslan, Fatih, Arts Assistenten Cardiologie, Team Medisch, Zwart, Bastiaan, Claessen, Bimmer E.P.M., Damman, Peter, Woudstra, Pier, Vink, Maarten A., Balder, J. Willem, Dickinson, Michael G., Badings, Erik A., Appelman, Yolande, van ’t Hof, Arnoud W.J., ten Berg, Jurriën M., and Arslan, Fatih

Published
2024

12. Invited Letter to editor (respons STRE-D-24–00176)

Author

van Vliet, Risco, Breedveld, Lennert, Heutinck, Annemieke A.J., Ockeloen, Bram H.A., van ’t Hof, Arnoud W.J., Moors, Xavier R.J., van Vliet, Risco, Breedveld, Lennert, Heutinck, Annemieke A.J., Ockeloen, Bram H.A., van ’t Hof, Arnoud W.J., and Moors, Xavier R.J.

Published
2024

13. Medically Treated Nonischemic Thin-Cap Fibroatheroma Lesions Versus Fractional Flow Reserve-Guided Complete Revascularization in Diabetic Patients

Author

Hommels, Tobias M., primary, Hermanides, Renicus S., additional, Fabris, Enrico, additional, Malinowski, Krzysztof P., additional, Berta, Balázs, additional, Roleder, Tomasz, additional, Alfonso, Fernando, additional, De Luca, Giuseppe, additional, Oemrawsingh, Rohit M., additional, Wojakowski, Wojciech, additional, van ‘t Hof, Arnoud W.J., additional, and Kedhi, Elvin, additional

Published
2023
Full Text
View/download PDF

15. Comparison of Outcomes and Intervention Among Patients With Non–ST-Segment Elevation Acute Myocardial Infarction of Those With a Left Circumflex Versus Those With a Non–Left Circumflex-Related Coronary Artery (From the ELISA-3 Trial)

Author

Badings, Erik A., Hermanides, Renicus S., The, Salem H.K., Dambrink, Jan-Henk E., Rasoul, Saman, Van Wijngaarden, Jan, Van 't Riet, Esther, Kolkman, Evelien, Remkes, Wouter S., Tjeerdsma, Geert, Van Der Wielen, Marloes L.J., Lok, Dirk J.A., Suryapranata, Harry, and Van 't Hof, Arnoud W.J.

Published
2018
Full Text
View/download PDF

16. Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial

Author

van Ginkel, Dirk Jan, primary, Bor, Willem L., additional, Dubois, Christophe L.F., additional, Aarts, Hugo M., additional, Rooijakkers, Maxim J.P., additional, van Bergeijk, Kees H., additional, Rosseel, Liesbeth, additional, Veenstra, Leo, additional, De Backer, Ole, additional, Van Mieghem, Nicolas M., additional, van der Kley, Frank, additional, Wilgenhof, Adriaan, additional, Leonora, Remigio, additional, Halim, Jonathan, additional, Schotborgh, Carl E., additional, Barbato, Emanuele, additional, Van Der Heyden, Jan A.S., additional, Frambach, Peter, additional, Ferdinande, Bert, additional, Mylotte, Darren, additional, Fabris, Enrico, additional, Rensing, Benno J.W.M., additional, Timmers, Leo, additional, Swaans, Martin J., additional, Brouwer, Jorn, additional, Nijenhuis, Vincent J., additional, Peper, Joyce, additional, Vriesendorp, Pieter A., additional, de Laat, Bas, additional, Ninivaggi, Marisa, additional, Stragier, Hendrik, additional, Voskuil, Michiel, additional, IJsselmuiden, Alexander J.J., additional, Hermanides, Renicus S., additional, Agostoni, Pierfrancesco, additional, van 't Hof, Arnoud W.J., additional, Wykrzykowska, Joanna J., additional, van Royen, Niels, additional, Delewi, Ronak, additional, and ten Berg, Jurrien M., additional

Published
2023
Full Text
View/download PDF

21. CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Author

Bergmeijer, Thomas O., Janssen, Paul W.A., Schipper, Jurjan C., Qaderdan, Khalid, Ishak, Maycel, Ruitenbeek, Rianne S., Asselbergs, Folkert W., van ‘t Hof, Arnoud W.J., Dewilde, Willem J.M., Spanó, Fabrizio, Herrman, Jean-Paul R., Kelder, Johannes C., Postma, Maarten J., de Boer, Anthonius, Deneer, Vera H.M., and ten Berg, Jurriën M.

Published
2014
Full Text
View/download PDF

25. Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

Author

Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., Boersma, Cornelis, Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., and Boersma, Cornelis

Abstract

Introduction: The POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2Y12 inhibitor strategy reduced bleeding rates compared with standard treatment with ticagrelor or prasugrel without increasing thrombotic event rates after primary percutaneous coronary intervention (PCI). Objective: In this analysis, we aimed to evaluate the cost effectiveness of a genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel. Methods: A 1-year decision tree based on the POPular Genetics trial in combination with a lifelong Markov model was developed to compare costs and quality-adjusted life-years (QALYs) between a genotype-guided and a standard P2Y12 inhibitor strategy in patients with myocardial infarction undergoing primary PCI. The cost-effectiveness analysis was conducted from a Dutch healthcare system perspective. Within-trial survival and utility data were combined with lifetime projections to evaluate lifetime cost effectiveness for a cohort of 1000 patients. Costs and utilities were discounted at 4 and 1.5%, respectively, according to Dutch guidelines for health economic studies. Besides deterministic and probabilistic sensitivity analyses, several scenario analyses were also conducted (different time horizons, different discount rates, equal prices for P2Y12 inhibitors, and equal distribution of thrombotic events between the two strategies). Results: Base-case analysis with a hypothetical cohort of 1000 subjects demonstrated 8.98 QALYs gained and €725,550.69 in cost savings for the genotype-guided strategy (dominant). The deterministic and probabilistic sensitivity analysis confirmed the robustness of the model and the cost-effectiveness results. In scenario analyses, the genotype-guided strategy remained dominant. Conclusion: In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel resulted in QALYs gained and cost s

Published
2022

26. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial

Author

Tavenier, Anne H, Hermanides, Renicus S, Ottervanger, Jan Paul, Tolsma, Rudolf, van Beurden, Antony, Slingerland, Robbert Jan, ter Horst, Peter G.J., Gosselink, A.T. Marcel, Dambrink, Jan-Henk E., van Leeuwen, Maarten A.H., Roolvink, Vincent, Kedhi, Elvin, Klungel, Olaf, Belitser, Svetlana V., Angiolillo, Dominick J., Pustjens, Tobias, Rasoul, Saman, Gho, Ben, Stein, Mera, Ruiters, Lex, van 't Hof, Arnoud W.J., Tavenier, Anne H, Hermanides, Renicus S, Ottervanger, Jan Paul, Tolsma, Rudolf, van Beurden, Antony, Slingerland, Robbert Jan, ter Horst, Peter G.J., Gosselink, A.T. Marcel, Dambrink, Jan-Henk E., van Leeuwen, Maarten A.H., Roolvink, Vincent, Kedhi, Elvin, Klungel, Olaf, Belitser, Svetlana V., Angiolillo, Dominick J., Pustjens, Tobias, Rasoul, Saman, Gho, Ben, Stein, Mera, Ruiters, Lex, and van 't Hof, Arnoud W.J.

Abstract

Aims Platelet inhibition induced by P2Y12 receptor antagonists in patients with ST-elevation myocardial infarction (STEMI) can be affected by concomitant use of opioids. The aim of this trial was to examine the effect of intravenous (iv) acetaminophen compared with iv fentanyl on P2Y12 receptor inhibition in patients with STEMI. Methods and results The Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial randomized 195 STEMI patients who were scheduled to undergo primary percutaneous coronary intervention (PCI) and were pre-treated with crushed ticagrelor to iv acetaminophen (N = 98) or iv fentanyl (N = 97) in the ambulance. The primary endpoint, consisting of the level of platelet reactivity units (PRU) measured immediately after primary PCI, was not significantly different between the study arms [median PRU 104 (IQR 37–215) vs. 175 (63–228), P = 0.18]. However, systemic levels of ticagrelor were significantly higher in the acetaminophen arm at the start of primary PCI [151 ng/mL (32–509) vs. 60 ng/mL (13–206), P = 0.007], immediately after primary PCI [326 ng/mL (94–791) vs. 115 ng/mL (38–326), P = 0.002], and at 1 h after primary PCI [488 ng/mL (281–974) vs. 372 ng/mL (95–635), P = 0.002]. Acetaminophen resulted in the same extent of pain relief when compared with fentanyl [reduction of 3 points on 10-step-pain scale before primary PCI (IQR 1–5)] in both study arms (P = 0.67) and immediately after PCI [reduction of 5 points (3–7); P = 0.96]. Conclusion The iv acetaminophen in comparison with iv fentanyl was not associated with significantly lower platelet reactivity in STEMI patients but resulted in significantly higher ticagrelor plasma levels and was effective in pain relief.

Published
2022

27. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Tavenier, Anne H, Hermanides, Renicus S, Ottervanger, Jan Paul, Tolsma, Rudolf, van Beurden, Antony, Slingerland, Robbert Jan, ter Horst, Peter G.J., Gosselink, A.T. Marcel, Dambrink, Jan-Henk E., van Leeuwen, Maarten A.H., Roolvink, Vincent, Kedhi, Elvin, Klungel, Olaf, Belitser, Svetlana V., Angiolillo, Dominick J., Pustjens, Tobias, Rasoul, Saman, Gho, Ben, Stein, Mera, Ruiters, Lex, van 't Hof, Arnoud W.J., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Tavenier, Anne H, Hermanides, Renicus S, Ottervanger, Jan Paul, Tolsma, Rudolf, van Beurden, Antony, Slingerland, Robbert Jan, ter Horst, Peter G.J., Gosselink, A.T. Marcel, Dambrink, Jan-Henk E., van Leeuwen, Maarten A.H., Roolvink, Vincent, Kedhi, Elvin, Klungel, Olaf, Belitser, Svetlana V., Angiolillo, Dominick J., Pustjens, Tobias, Rasoul, Saman, Gho, Ben, Stein, Mera, Ruiters, Lex, and van 't Hof, Arnoud W.J.

Published
2022

28. Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., ten Berg, Jurriën M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., and ten Berg, Jurriën M.

Published
2022

29. Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., Boersma, Cornelis, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., and Boersma, Cornelis

Published
2022

30. Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

Author

Verpleegafdeling Cardiologie, Team Medisch, Circulatory Health, Apotheek Klinische Farmacie, Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., Boersma, Cornelis, Verpleegafdeling Cardiologie, Team Medisch, Circulatory Health, Apotheek Klinische Farmacie, Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., and Boersma, Cornelis

Published
2022

31. Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial

Author

Verpleegafdeling Cardiologie, Apotheek Klinische Farmacie, Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., ten Berg, Jurriën M., Verpleegafdeling Cardiologie, Apotheek Klinische Farmacie, Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., and ten Berg, Jurriën M.

Published
2022

36. Facilitated reperfusion with prehospital glycoprotein IIb/IIIa inhibition: predictors of complete ST-segment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial: Correlates of reperfusion before primary PCI

Author

Heestermans, Ton, Suryapranata, Harry, ten Berg, Jurriën M., Mosterd, Arend, Gosselink, A.T. Marcel, Kochman, Waclav, Dill, Thorsten, van Houwelingen, Gert, Kolkman, Evelien, van Werkum, Jochem W., Zijlstra, Felix, Hamm, Christian, and van 't Hof, Arnoud W.J.

Published
2011
Full Text
View/download PDF

37. Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial

Author

Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., ten Berg, Jurriën M., Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
STEMI, clopidogrel, Radiology Nuclear Medicine and imaging, glycoprotein IIb/IIIa inhibitors, primary percutaneous coronary intervention, Cardiology and Cardiovascular Medicine, ticagrelor
Abstract

Background: Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI), although discussion about its clinical benefit is ongoing. Methods: GPI use was analyzed in this subanalysis of the POPular Genetics trial, which randomized STEMI patients to CYP2C19 genotype-guided treatment (clopidogrel or ticagrelor) or standard treatment with ticagrelor/prasugrel. The composite thrombotic endpoint consisted of cardiovascular death, myocardial infarction (MI), definite stent thrombosis, and stroke at 30 days. The combined bleeding endpoint consisted of Platelet Inhibition and Patient Outcomes (PLATO) major and minor bleeding at 30 days. Univariable and multivariable analyses in addition to a propensity score-matched (PSM) analysis were conducted. Results: In total, 2378 patients, of whom 1033 received GPI and 1345 did not, were included. In multivariable analysis, GPI administration was associated with fewer thrombotic events (hazard ratio [HR] 0.22, 95% confidence interval [CI] 0.09–0.55) and MIs (HR 0.24, 95% CI 0.08–0.73). Furthermore, GPI administration was associated with an increase in bleedings (HR 2.02, 95% CI 1.27–3.19), driven by minor bleedings (HR 2.32, 95% CI 1.43–3.76), without a significant difference in major bleedings (HR 0.69, 95% CI 0.19–2.57). In the PSM analysis, no significant association was found. Conclusion: In STEMI patients undergoing primary PCI, GPI administration was associated with a reduction in thrombotic events at a cost of an increase in (mostly minor) bleedings in multivariable analysis, while propensity score analysis did not show significant associations.

Published
2022

38. The golden hour of prehospital reperfusion with triple antiplatelet therapy: A sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy

Author

Heestermans, Ton, van 't Hof, Arnoud W.J., ten Berg, Jurriën M., van Werkum, Jochem W., Boersma, Eric, Mosterd, Arend, Stella, Pieter R., van Zoelen, Arthur B., Gosselink, A.T. Marcel, Kochman, Waclav, Dill, Thorsten, Koopmans, Petra C., van Houwelingen, Gert, Zijlstra, Felix, and Hamm, Christian

Published
2010
Full Text
View/download PDF

45. Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction

Author

Bor, Willem L., primary, Zheng, Kai L., additional, Tavenier, Anne H., additional, Gibson, C. Michael, additional, Granger, Christopher B., additional, Bentur, Ohad, additional, Lobatto, Rita, additional, Postma, Sonja, additional, Coller, Barry S., additional, van ’t Hof, Arnoud W.J., additional, and ten Berg, Jurrien M., additional

Published
2021
Full Text
View/download PDF

46. Clopidogrel Versus Ticagrelor or Prasugrel after Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Author

Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., Ten Berg, Jurriën M., Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., and Ten Berg, Jurriën M.

Abstract

Background: Guidelines favor ticagrelor or prasugrel over clopidogrel in patients with myocardial infarction. However, the POPular Genetics trial (Patient Outcome After Primary Percutaneous Coronary Intervention [PCI]) showed that in patients with primary PCI, a CYP2C19 genotype-guided strategy was associated with a lower bleeding risk without increasing thrombotic risk, compared with routine ticagrelor/prasugrel treatment. Nevertheless, optimal P2Y12 inhibitor treatment in specific CYP2C19 genetic subgroups is still a subject of debate. Methods: A prespecified subanalysis of the POPular Genetics trial was performed, using patients in whom CYP2C19∗2, ∗3, and ∗17 genotypes was determined. Two different analyses were planned. The first assessed the effect of the CYP2C19∗17 allele in clopidogrel-treated patients. The second compared the effect of clopidogrel in noncarriers of a loss-of-function allele with ticagrelor/prasugrel-treated patients, irrespective of CYP2C19 genotype. Main outcomes were a thrombotic outcome (cardiovascular death, myocardial infarction, stent thrombosis, and stroke) and a bleeding outcome (PLATO [Platelet Inhibition and Patient Outcomes] major and minor bleeding) after 12 months. Results: A total of 2429 patients were used for analyses. In the first analysis, the CYP2C19∗17 polymorphism was not found to have a significant influence on thrombotic (adjusted hazard ratio, 0.95 [95% CI, 0.45-2.02]) or bleeding outcomes (adjusted hazard ratio, 0.74 [95% CI, 0.48-1.18]). In the second analysis, clopidogrel was associated with a lower number of bleeding events compared with ticagrelor/prasugrel (9.9% versus 11.7%, adjusted hazard ratio, 0.74 [95% CI, 0.56-0.96]), without a significant increase in thrombotic events (3.4% versus 2.5%, adjusted hazard ratio, 1.14 [95% CI, 0.68-1.90]). Conclusions: In patients with primary PCI not carrying a CYP2C19 loss-of-function allele, the use of clopidogrel compared with ticagrelor or prasugrel was associated wi

Published
2021

47. Clopidogrel Versus Ticagrelor or Prasugrel after Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., Ten Berg, Jurriën M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., and Ten Berg, Jurriën M.

Published
2021

48. Clopidogrel Versus Ticagrelor or Prasugrel after Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Author

Circulatory Health, Team Medisch, Apotheek Klinische Farmacie, Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., Ten Berg, Jurriën M., Circulatory Health, Team Medisch, Apotheek Klinische Farmacie, Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., and Ten Berg, Jurriën M.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results